Cargando…

Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis

It remains unclear whether mitochondrial modulators (MMs) are beneficial in the treatment of obsessive–compulsive and related disorders. Thus, in an attempt to answer this clinical question, we performed a systematic review and a random-effects meta-analysis of double-blind, randomized, placebo-cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Kishi, Taro, Sakuma, Kenji, Iwata, Nakao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240021/
https://www.ncbi.nlm.nih.gov/pubmed/35764619
http://dx.doi.org/10.1038/s41398-022-02026-5
_version_ 1784737445828362240
author Kishi, Taro
Sakuma, Kenji
Iwata, Nakao
author_facet Kishi, Taro
Sakuma, Kenji
Iwata, Nakao
author_sort Kishi, Taro
collection PubMed
description It remains unclear whether mitochondrial modulators (MMs) are beneficial in the treatment of obsessive–compulsive and related disorders. Thus, in an attempt to answer this clinical question, we performed a systematic review and a random-effects meta-analysis of double-blind, randomized, placebo-controlled trials. The primary outcome was change in overall symptoms as measured using standardized rating scales. Other outcomes were response to treatment; improvement in anxiety-related scales scores, depression-related scale scores, Clinical Global Impression Severity Scale (CGI-S) scores, and Sheehan Disability Scale (SDS) scores; all-cause discontinuation; and individual adverse events. We calculated the standardized mean differences for continuous outcomes and risk ratios for dichotomous outcomes with 95% confidence intervals. We reviewed 17 studies (n = 629, 72.62% female; duration = 2–20 weeks; mean age = 30.47 years) of MMs: eicosapentaenoic acid (K = 1), folic acid (K = 1), lithium (K = 1), N-acetylcysteine (K = 10), inositol (K = 3), and silymarin (K = 1). MMs outperformed placebo in overall improvement in symptoms (p < 0.01) and in improving anxiety-related scale scores (p = 0.05). Subgroup analysis of individual MMs revealed that although overall symptoms were better improved by N-acetylcysteine (p < 0.01) and lithium (p = 0.04), no MMs outperformed placebo in terms of improving anxiety-related scale scores. Neither pooled nor individual MMs outperformed placebo in improving response to treatment, depression-related scale scores, CGI-S scores, SDS scores, or all-cause discontinuation. N-acetylcysteine was no more associated with a higher incidence of individual adverse events including gastrointestinal symptoms, than placebo. In conclusion, N-acetylcysteine was beneficial in the treatment of obsessive–compulsive and related disorders. However, further study with larger samples is necessary to confirm this finding.
format Online
Article
Text
id pubmed-9240021
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-92400212022-06-30 Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis Kishi, Taro Sakuma, Kenji Iwata, Nakao Transl Psychiatry Article It remains unclear whether mitochondrial modulators (MMs) are beneficial in the treatment of obsessive–compulsive and related disorders. Thus, in an attempt to answer this clinical question, we performed a systematic review and a random-effects meta-analysis of double-blind, randomized, placebo-controlled trials. The primary outcome was change in overall symptoms as measured using standardized rating scales. Other outcomes were response to treatment; improvement in anxiety-related scales scores, depression-related scale scores, Clinical Global Impression Severity Scale (CGI-S) scores, and Sheehan Disability Scale (SDS) scores; all-cause discontinuation; and individual adverse events. We calculated the standardized mean differences for continuous outcomes and risk ratios for dichotomous outcomes with 95% confidence intervals. We reviewed 17 studies (n = 629, 72.62% female; duration = 2–20 weeks; mean age = 30.47 years) of MMs: eicosapentaenoic acid (K = 1), folic acid (K = 1), lithium (K = 1), N-acetylcysteine (K = 10), inositol (K = 3), and silymarin (K = 1). MMs outperformed placebo in overall improvement in symptoms (p < 0.01) and in improving anxiety-related scale scores (p = 0.05). Subgroup analysis of individual MMs revealed that although overall symptoms were better improved by N-acetylcysteine (p < 0.01) and lithium (p = 0.04), no MMs outperformed placebo in terms of improving anxiety-related scale scores. Neither pooled nor individual MMs outperformed placebo in improving response to treatment, depression-related scale scores, CGI-S scores, SDS scores, or all-cause discontinuation. N-acetylcysteine was no more associated with a higher incidence of individual adverse events including gastrointestinal symptoms, than placebo. In conclusion, N-acetylcysteine was beneficial in the treatment of obsessive–compulsive and related disorders. However, further study with larger samples is necessary to confirm this finding. Nature Publishing Group UK 2022-06-28 /pmc/articles/PMC9240021/ /pubmed/35764619 http://dx.doi.org/10.1038/s41398-022-02026-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Kishi, Taro
Sakuma, Kenji
Iwata, Nakao
Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis
title Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis
title_full Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis
title_fullStr Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis
title_full_unstemmed Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis
title_short Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis
title_sort mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240021/
https://www.ncbi.nlm.nih.gov/pubmed/35764619
http://dx.doi.org/10.1038/s41398-022-02026-5
work_keys_str_mv AT kishitaro mitochondrialmodulatorsforobsessivecompulsiveandrelateddisordersasystematicreviewandmetaanalysis
AT sakumakenji mitochondrialmodulatorsforobsessivecompulsiveandrelateddisordersasystematicreviewandmetaanalysis
AT iwatanakao mitochondrialmodulatorsforobsessivecompulsiveandrelateddisordersasystematicreviewandmetaanalysis